Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Don Dorsey who wrote (1948)	7/23/1999 12:00:00 PM
From: Don Dorsey	Read Replies (2) \| Respond to of 2135

NEW YORK, July 22 (Reuters) - Stuart Weisbrod, former star drug analyst at Merrill Lynch and Prudential Securities, told Business Week he thinks two biotech stocks may be showing signs of life, but is short on others. Weisbrod, who formed Merlin BioMed Asset Management, is short on EntreMed Inc. , whose stock jettisoned from 12 to 86 in one day after the New York Times reported the company had developed a product that starves tumours, according to the magazine. The stock closed Thursday at $22.44. Weisbrod thinks it could hit $10, the magazine said.